Knight Therapeutics signs licensing deal with Supernus for Qelbree in Canada
Qelbree is a commercially available prescription medication in the US to treat ADHD and Supernus has granted Knight…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Dec 23
Qelbree is a commercially available prescription medication in the US to treat ADHD and Supernus has granted Knight…
20 Dec 23
COM503 is a potential first-in-class, high affinity antibody that inhibits the progression of cancer by releasing endogenous IL-18…
19 Dec 23
Otsuka will acquire exclusive rights to market donidalorsen in Europe in exchange for an upfront payment of $65m,…
19 Dec 23
Under the terms of the agreement, Biocytogen will provide Ona with the opportunity to assess Biocytogen's proprietary fully…
19 Dec 23
Under the terms of the agreement, Lilly will remain the marketing authorisation holder and will produce migraine drugs…
15 Dec 23
Teva will obtain exclusive worldwide rights to develop and commercialise Biolojic’s BD9, a multibody designed as a multi-specific…
15 Dec 23
FoundationOne CDx and FoundationOne Liquid CDx are the company’s tissue-based and liquid-based comprehensive genomic profiling tests
14 Dec 23
Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY
08 Dec 23
Ponvory is a daily oral selective sphingosine-1-phosphate receptor 1 modulator, approved by the US FDA and Health Canada…
07 Dec 23
COYA 302 is a biologic combination therapy candidate that has a dual immunomodulatory mechanism of action to improve…